Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 9/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.51 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24101021 | 0.87 | HCAR3 (0.67) | HCAR3KDM4EHCAR2MAPT | |
| SCHEMBL186420 | 0.83 | HCAR3 (1.00) | HCAR3HCAR2MAPT | |
| SCHEMBL13043454 | 0.83 | HCAR3 (0.57) | HCAR3MAPK1KDM4EL3MBTL1GABRA5 | |
| SCHEMBL11184789 | 0.82 | HCAR3 (0.72) | HCAR3MAPK1KDM4EL3MBTL1GABRA5 | |
| SCHEMBL24774175 | 0.81 | MAPK1 (0.51) | HCAR3MAPK1KDM4EL3MBTL1GABRA5 | |
| SCHEMBL1854705 | 0.81 | MAPK1 (0.59) | HCAR3MAPK1KDM4EL3MBTL1 | |
| SCHEMBL11546416 | 0.81 | HCAR3 (0.73) | HCAR3HCAR2ADRA2AADRA2BADRA2C | |
| SCHEMBL6984008 | 0.81 | HCAR3 (0.68) | HCAR3MAPK1KDM4EL3MBTL1GABRA5 | |
| SCHEMBL19151089 | 0.81 | MAPK1 (0.54) | HCAR3MAPK1KDM4EL3MBTL1MAPT | |
| SCHEMBL20722658 | 0.80 | CA1 (0.62) | HCAR3MAPK1KDM4EL3MBTL1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9243000-B2 | Thia-triaza-indacenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| EP-2421871-B1 | THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2015-09-16 | — | — | EP | disclosed |
| EP-2350084-B1 | TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (PI3-KINASES) INHIBITOR | BOEHRINGER INGELHEIM INT (DE) | 2015-06-24 | — | — | EP | disclosed |
| EP-2421872-B1 | THIA-TRIAZA-AS-INDACENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2015-06-10 | — | — | EP | disclosed |
| US-8653097-B2 | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (P13-kinases) inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8604022-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2013-12-10 | — | — | US | disclosed |
| US-8304556-B2 | Thiazolyl-dihydro-indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8288379-B2 | Thia-triaza-cyclopentazulenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| CN-101611014-B | Amidopyrazoles as FGFR inhibitors | ASTRAZENECA AB | 2012-05-30 | — | — | CN | disclosed |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | ASTRAZENECA AB | 2012-05-24 | — | — | US | disclosed |
| US-5834468-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, ANALGESICS TREATING RHEUMATIC DISEASE, BONE DISORDER, INJURIES | ZENECA LIMITED (GB) | 1998-11-10 | — | — | US | disclosed |
| CN-1193966-A | Aromatic compounds and pharmaceutical compositions containing them | ZENECA LTD (GB) | 1998-09-23 | — | — | CN | disclosed |
| EP-0847391-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1998-06-17 | — | — | EP | disclosed |
| EP-0835246-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1998-04-15 | — | — | EP | disclosed |
| CN-1154106-A | Aromatic amino ethers as analgesic agents | ZENECA LTD (GB) | 1997-07-09 | — | — | CN | disclosed |
| EP-0773930-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1997-05-21 | — | — | EP | disclosed |
| WO-1997000863-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1997-01-09 | — | — | WO | disclosed |
| WO-1997000864-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1997-01-09 | — | — | WO | disclosed |
| EP-0752421-A1 | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists | ZENECA LIMITED (GB) | 1997-01-08 | — | — | EP | disclosed |
| WO-1996003380-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HCAR3 4684/4885MAPK1 310/4885KDM4E 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.